Helem Vílchez

Sociodemographic, clinical, and immunological factors associated with SARS-CoV-2 diagnosis and severe COVID-19 outcomes in people living with HIV: a retrospective cohort study

Daniel K. Nomah, Juliana Reyes‐Urueña, Yesika Díaz et al. · The Lancet HIV · 2021 · 110 citations · Full text

Public Health, Health Sciences, Infectious Diseases +17

Dual Therapy With Darunavir and Ritonavir Plus Lamivudine vs Triple Therapy With Darunavir and Ritonavir Plus Tenofovir Disoproxil Fumarate and Emtricitabine or Abacavir and Lamivudine for Maintenance of Human Immunodeficiency Virus Type 1 Viral Suppression: Randomized, Open-Label, Noninferiority DUAL-GESIDA 8014-RIS-EST45 Trial

Federico Pulido, Esteban Ribera, María Lagarde et al. · Clinical Infectious Diseases · 2017 · 102 citations · Full text

Pharmacy, Infectious Diseases, Pharmacotherapy +17

Identification and validation of clinical phenotypes with prognostic implications in patients admitted to hospital with COVID-19: a multicentre cohort study

Belén Gutiérrez‐Gutiérrez, Alberto M. Borobia, Antonio J. Carcas et al. · The Lancet Infectious Diseases · 2021 · 102 citations · Full text

Medicine, Clinical Sciences, Infectious Diseases +13

Effectiveness of Fosfomycin for the Treatment of Multidrug-Resistant <i>Escherichia coli</i> Bacteremic Urinary Tract Infections

Jesús Sojo-Dorado, Inmaculada López-Hernández, Clara Rosso-Fernández et al. · JAMA Network Open · 2022 · 87 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +17

Efficacy and safety of an early oral switch in low-risk Staphylococcus aureus bloodstream infection (SABATO): an international, open-label, parallel-group, randomised, controlled, non-inferiority trial

Achim J. Kaasch, Luis Eduardo López-Cortés, Jesús Rodríguez‐Baño et al. · The Lancet Infectious Diseases · 2024 · 81 citations

Pharmacy, Pharmacotherapy, Infection Prevention +13